Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

View All Documentation

Y0000576

Lorazepam for system suitability

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

(±)-Lorazepam, 7-Chloro-5-(2-chlorophenyl)-1,3-dihydro-3-hydroxy-2H-1,4-benzodiazepin-2-one

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C15H10Cl2N2O2
Numéro CAS:
846-49-1
Poids moléculaire :
321.16
Numéro MDL:
MFCD00063406
Code UNSPSC :
41116107
ID de substance PubChem :
329831029
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

lorazepam

Fabricant/nom de marque

EDQM

Contrôle du médicament

regulated under CDSA - not available from Sigma-Aldrich Canada; psicótropo (Spain); Decreto Lei 15/93: Tabela IV (Portugal)

Application(s)

pharmaceutical (small molecule)

Format

neat

Chaîne SMILES 

OC1N=C(c2ccccc2Cl)c3cc(Cl)ccc3NC1=O

InChI

1S/C15H10Cl2N2O2/c16-8-5-6-12-10(7-8)13(19-15(21)14(20)18-12)9-3-1-2-4-11(9)17/h1-7,15,21H,(H,18,20)

Clé InChI

DIWRORZWFLOCLC-UHFFFAOYSA-N

Informations sur le gène

human ... GABRA1(2554) , GABRA2(2555) , GABRA3(2556) , GABRA4(2557) , GABRA5(2558) , GABRA6(2559) , GABRB1(2560) , GABRB2(2561) , GABRB3(2562) , GABRD(2563) , GABRE(2564) , GABRG1(2565) , GABRG2(2566) , GABRG3(2567) , GABRP(2568) , GABRQ(55879)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Catégories apparentées

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Lorazepam for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

1370327

Lorazepam Related Compound A, United States Pharmacopeia (USP) Reference Standard

L0750500

Lorazepam, European Pharmacopoeia (EP) Reference Standard

1370305

Lorazepam, United States Pharmacopeia (USP) Reference Standard

1370338

Lorazepam Related Compound B, United States Pharmacopeia (USP) Reference Standard

Y0000718

Lorazepam impurity D, European Pharmacopoeia (EP) Reference Standard

1370349

Lorazepam Related Compound C, United States Pharmacopeia (USP) Reference Standard

1370350

Lorazepam Related Compound D, United States Pharmacopeia (USP) Reference Standard

1370360

Lorazepam Related Compound E, United States Pharmacopeia (USP) Reference Standard

BP434

Lorazepam, British Pharmacopoeia (BP) Reference Standard

BP376

6-Chloro-4-(2-chlorophenyl)quinazoline-2-carboxaldehyde, British Pharmacopoeia (BP) Reference Standard

Pictogrammes

Health hazard
GHS08

Mention d'avertissement

Warning

Mentions de danger

H361d

Classification des risques

Repr. 2

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Jonathan Rosenson et al.
The Journal of emergency medicine, 44(3), 592-598 (2012-09-25)
Acute alcohol withdrawal syndrome (AAWS) is encountered in patients presenting acutely to the Emergency Department (ED) and often requires pharmacologic management. We investigated whether a single dose of intravenous (i.v.) phenobarbital combined with a standardized lorazepam-based alcohol withdrawal protocol decreases
Thomas P Bravo et al.
The neurologist, 19(1), 30-33 (2012-12-28)
Psychogenic nonepileptic seizures (PNES) are commonly encountered problem in neurological practice and usually are accompanied by other psychiatric comorbidities. Despite its prevalence and profound impact on patients and families, there have been few trials addressing treatment. Cognitive behavioral therapy may
Preemptive use of palliative sedation and amyotrophic lateral sclerosis.
Judith A C Rietjens et al.
Journal of pain and symptom management, 44(3), e5-e7 (2012-09-04)
Natalie L Jacobowski et al.
Journal of psychiatric practice, 19(1), 15-28 (2013-01-22)
Delirious mania is a severe but under-recognized neuropsychiatric syndrome characterized by the rapid onset of delirium, mania, and psychosis, not associated with a prior toxicity, physical illness, or mental disorder. Catatonia is often a prominent feature of the syndrome. While
G Marti et al.
Human & experimental toxicology, 32(3), 332-334 (2012-11-24)
Ritalin® (methylphenidate) is an amphetamine-like prescription stimulant commonly used in the treatment of attention deficit hyperactivity disorder in children and adults. Recently, the recreational use of Ritalin has increased, particularly among young adults. Well-known symptoms of intoxication include signs of
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique